Three companies recently announced progression in their clinical research for next-generation Covid-19 vaccines: INOVIO, ...

have pioneered an influenza virus vector-based nasal spray vaccine platform and developed a nasal spray H5N1 avian influenza ...

The new nasal vaccine only needs one dose and produces reliable immunity right at the site where the virus enters the body.

An inhalable version of a single-shot, adenovirus-based viral vector vaccine might provide a new option for COVID-19 vaccination. In October 2021, the World Health Organization set a target for ...

AZD1222, developed by the University of Oxford and licenced to AstraZeneca, was among the first vaccines created to protect against COVID-19. A non -replicating viral vector vaccine which was ...

TASS/. Mass vaccination with a coronavirus vaccine developed by Russia’s State Research Center of Virology and Biotechnology Vector is expected to take place in 2021, the center's Director ...

Researchers have pioneered an influenza virus vector-based nasal spray vaccine platform and developed a nasal spray H5N1 ...

Scientists have pioneered an influenza virus vector-based nasal spray vaccine platform and developed a nasal spray H5N1 avian influenza vaccine. During the early COVID-19 pandemic, this platform ...